Home
Search
Category
Compounds
Status
Download
Contacts
Resources



Compound category: Organic compounds
(total 903 related compounds in database, current show from 1 to 10)
 
Compound name 2D structure Target pathogen(s) Related VF/VFcategory Max phase Reference(s)
Sibofimloc Depiction based on curated SMILES HO HO HO HO O OH OH HO HO O N CH 3 O Escherichia Adherence Phase II trial Chevalier G, et al. 2021. Microbiome; Reinisch W, et al. 2022. J Gastroenterol Hepatol
Fluorothiazinon Depiction based on curated SMILES OH O S F F H 3 C NH O N N O Acinetobacter
Chlamydia
Klebsiella
Pseudomonas
Salmonella
Biofilm
TTSS (Type III secretion system)
Biofilm
TTSS (Type III secretion system)
TTSS (SPI-1 encode); TTSS (SPI-2 encode)
Preclinical (in vivo)
Preclinical (in vivo)
Preclinical (in vitro)
Preclinical (in vivo)
Phase II trial
Bondareva NE, et al. 2022. J Antibiot (Tokyo)
Zigangirova NA, et al. 2012. Acta Naturae; Koroleva EA, et al. 2015. Biomed Res Int; Zigangirova NA, et al. 2016. J Med Microbiol
Tsarenko SV, et al. 2023. J Antibiot (Tokyo)
Sheremet AB, et al. 2018. Biomed Res Int
Nesterenko LN, et al. 2016. J Antibiot (Tokyo); Zigangirova NA, et al. 2021. J Antibiot (Tokyo)
Zosurabalpin Depiction based on curated SMILES NH 2 NH 2 N O OH N H N O N H S CH 3 N H O N H O Acinetobacter LPS Phase I trial Pahil KS, et al. 2024. Nature; Que W, et al. 2024. Trends Mol Med
N-(2-{(2Z)-2-[1-(1,3-benzodioxol-5-ylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]hydrazinyl}-2-oxoethyl)pyridine-3-carboxamide Depiction based on curated SMILES O N O N H O O N N H N O Acinetobacter Regulation Preclinical (in vivo) Trebosc V, et al. 2022. Virulence
Auranofin Depiction based on curated SMILES + Au H 3 C O O H 3 C O O CH 3 O O _ S O CH 3 O O H 3 C H 3 C H 3 C P Clostridium CDT (Clostridium difficile toxin) Preclinical (in vivo) AbdelKhalek A, et al. 2019. Int J Antimicrob Agents; Hutton ML, et al. 2020. J Antimicrob Chemother; Abutaleb NS, et al. 2020. Sci Rep
3-Methylthio-1,4-diphenyl-1H-1,3,4-triazolium Depiction based on curated SMILES N H 3 C + N N S Escherichia Heat-labile toxin (LT) Preclinical (in vivo) Hovey BT, et al. 1999. J Mol Biol
7-[3-methyl-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2H-isoquinolin-1-one Depiction based on curated SMILES N H OH OH OH OH O O O CH 3 Escherichia Type 1 fimbriae Preclinical (in vivo) Jarvis C, et al. 2016. ChemMedChem
(3R)-5-Oxo-6-(morpholinomethyl)-7-(1-naphthylmethyl)-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt Depiction based on curated SMILES O _ O O N + Li N O H S Escherichia Type 1 fimbriae; P fimbriae Preclinical (in vivo) Pinkner JS, et al. 2006. Proc Natl Acad Sci U S A
(3R)-5-Oxo-6-(dimethylaminomethyl)-7-(1-naphthylmethyl)-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt Depiction based on curated SMILES _ O N H 3 C N CH 3 + Li O H S O Escherichia Type 1 fimbriae; P fimbriae Preclinical (in vivo) Pinkner JS, et al. 2006. Proc Natl Acad Sci U S A
(3R)-5-Oxo-6-(dimethylaminomethyl)-7-methyl-8-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3beta-carboxylic acid lithium salt Depiction based on curated SMILES CH 3 H 3 C N _ O O + Li S H N O CH 3 Escherichia Type 1 fimbriae; P fimbriae Preclinical (in vivo) Pinkner JS, et al. 2006. Proc Natl Acad Sci U S A
   


NOTE: for more interactive and statistic charts, please visit the JavaScript-rich interface of VFDB.



Page  1  2  3  4  5  6  7  8  9  10  11  ...  91



Back to top
2004-2024 NIPB, CAMS&PUMC